

# Recent Advances in Various Heterocyclic Compounds as Anticancer Agents and Their Applications

Dr. Sumathi K.<sup>1\*</sup>; Yuvarani S.<sup>1</sup>; Dr. Venkatachalam T.<sup>1</sup>; Dr. Chitra A.<sup>1</sup>;  
Kalpana Devi M.<sup>1</sup>; Dr. Senthil Kumar N.<sup>1</sup>

<sup>1\*</sup>Professor Department of Pharmaceutical Chemistry

<sup>1</sup>JKKMMRF's Annai JKK Sampoorani Ammal College of Pharmacy, B. Komarapalayam, Namakkal the  
Tamil Nadu Dr. MGR Medical University, Chennai SSM College of Pharmacy, Jambai, Erode

Corresponding Author: Dr. Sumathi K.<sup>1\*</sup>

Publication Date: 2026/09/10

**Abstract:** The World Health Organization (WHO) estimates that there will be approximately 22 million new cases of cancer by 2030, making it one of the leading causes of death globally. The urgent need for efficient prevention, diagnosis, and treatment methods is highlighted by this increasing incidence. Medicinal chemistry, one of the many fields involved in the search for anticancer drugs, is essential in creating compounds that minimize toxicity while specifically targeting cancer cells. Because of their structural diversity, distinctive physicochemical characteristics, and wide range of biological activity, heterocyclic compounds which are defined by ring structures containing heteroatoms like nitrogen, oxygen, or sulfur are especially valuable in this context. Heterocyclic scaffolds form the foundation of many approved anticancer drugs, interacting with important biological targets such as DNA, enzymes, and cellular receptors to modulate multiple disrupted pathways in cancer cells (e.g., cell proliferation, apoptosis, DNA replication, tumor signaling). Nitrogen, sulfur, and oxygen-containing heterocycles represent an important tool for targeting these pathways due to the ability to provide these interactions, thus contributing significantly to drug discovery. Although promising, heterocyclic compounds pose significant challenges because of their poor solubility, limited bioavailability, off-target toxicity, and drug resistance. Structure-activity relationship (SAR) studies are used to provide guidance on rational changes for improved selectivity and reductions of adverse events. Advances in nanotechnology represent new opportunities for overcoming these issues. The use of nanocarrier drug delivery systems, i.e., nanoparticles, liposomes, or polymers, has been shown to enhance solubility, circulation lifetime, and accumulation of drug at the targeted tumor through multiple mechanisms, including the enhanced permeability and retention (EPR) effect through improving pharmacokinetic and pharmacodynamic parameters. The review emphasizes the role of heterocyclics in treatment of cancer including their function, mechanisms of action in cancer treatment, potential uses in medicine, their challenges for development, and potential new methods of drug delivery (such as nanoparticles). The first-half of the review summarizes what is known from current studies and gives an example of a rational design process that has produced better efficacy; selectivity; and safety for future heterocyclic antitumor drugs.

**Keywords:** Heterocyclic Compounds, Cancer Therapy, Cytotoxicity, Drug Discovery.

**How to Cite:** Dr. Sumathi K.; Yuvarani S.; Dr. Venkatachalam T.; Dr. Chitra A.; Kalpana Devi M.; Dr. Senthil Kumar N. (2026) Recent Advances in Various Heterocyclic Compounds as Anticancer Agents and Their Applications. *International Journal of Innovative Science and Research Technology*, 11(8), 3316-3325. <https://doi.org/10.38124/ijisrt/26aug1204>

## I. INTRODUCTION

Cancer represents the most complicated disease which develops through multiple factors, as it causes uncontrolled cell growth and abnormal cell division and enables cancerous cells to spread into nearby tissues and distant body parts. The condition develops through a combination of three factors which include genetic mutations and epigenetic changes and

exposure to environmental pollutants and dietary contaminants and viral infections and chemical substances and ionizing radiation. The factors break down the precise cellular systems which maintain cell cycle control and DNA repair processes and apoptosis because of their uncontrolled behavior which permits tumor development. Every year cancer results in millions of fatalities which create a worldwide public health crisis.

The latest global statistics show that more than 20 million new cancer cases emerge each year with about 10 million deaths and the burden will rise by almost 60 percent during the next 20 years which will create major healthcare system challenges for both people and communities. The different cancer rates between regions show how healthcare systems and socioeconomic conditions and people's daily habits and their ability to find and receive medical care differ from one place to another. Present-day cancer treatment methods which include chemotherapy and radiation therapy and immunotherapy and targeted therapies continue to struggle against several treatment obstacles because the methods produce systemic toxic effects and lack targeted treatment and patients develop multidrug resistance and experience unwanted treatment outcomes. The conventional chemotherapeutic agents which include alkylating agents and antimetabolites and antibiotics and plant-derived compounds show effectiveness in particular situations because they often lead to harm against healthy tissues which results in severe treatment side effects.

Heterocyclic compounds constitute a diverse family of organic molecules which display cyclic structures that contain one or more heteroatoms. Heterocycles contain other heteroatoms but nitrogen and oxygen and sulfur serve as the primary elements which scientists study. The compounds belong to a fundamental category of organic substances which researchers use to study various biological systems because they demonstrate effectiveness against multiple medical conditions. Heterocyclic compounds exist throughout the natural world while being present in many artificial compounds that sustain life. Heterocyclic rings exist

in many biologically significant molecules which include vitamins and amino acids and antibiotics and alkaloids and hormones and hemoglobin and numerous artificial substances and dyes. Heterocycles function as therapeutic agents because they treat various common medical conditions.

The field of medicinal chemistry depends on nitrogen-containing heterocycles because they function as essential natural products which exhibit physiological activity. The research community attributes growing significance to indole and imidazole and pyrrole and triazole and piperazine because these nitrogen-bearing heterocycles serve as research tools for drug development and chemical synthesis. The FDA has approved a significant number of drugs which contain oxygen-containing heterocycles because these compounds form essential components for many therapeutic structures. Benzothiazole and thiophene belong to the category of sulfur-containing heterocycles which exhibit biological activities that range from anticancer to antimicrobial to antiviral to anti-inflammatory effects.

People use sulfur-containing compounds for their medicinal purposes together with their function as flavoring substances. Numerous FDA-approved drugs incorporate nitrogen and sulfur heterocycles, including anastrozole, abemaciclib, tamoxifen, 5-fluorouracil, clopidogrel, and raloxifene, which are used to treat diseases such as breast cancer, diabetes, and several other conditions. The prevalence of heterocyclic scaffolds in both natural and synthetic molecules underscores their central role in medicinal chemistry, drug development, and therapeutic applications.




Fig 1 Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds

➤ *Importance of Heterocyclic Compounds in Anticancer Drug Discovery:*

Heterocyclic compounds serve as "privileged structures" in medicinal chemistry because they have the ability to attach to various biological targets while demonstrating multiple medicinal effects.

• *The Key Benefits of Heterocyclic Compounds Include:*

- ✓ The ability to create different structural forms.
- ✓ Their capacity to produce strong biological effects.
- ✓ People show better demonstration of their target biological activities.
- ✓ People show strengthened capacity to attach to biological molecular targets.

The anticancer drug development process uses heterocyclic scaffolds such as pyridine, indole, quinoline, triazole, imidazole, and benzimidazole. These molecules function by blocking enzyme activity, disrupting DNA replication, and controlling the cancer-related signaling pathways.

➤ *Drugs Used for Cancer Treatment:*

Anticancer agents are challenging to classify because their various mechanisms create multiple paths for their classification. The agents existed in historical studies as six distinct groups which included (a) alkylating agents, (b) antimetabolites, (c) natural products, (d) hormones and hormone antagonists, (e) miscellaneous agents, and (f) others. The miscellaneous category contains those important agents which scientists developed recently because their mechanisms operate differently than established methods.

Alkylating agents and related compounds create covalent bonds with DNA, which stops DNA replication and leads to errors in cell division. Antimetabolites disrupt DNA synthesis through their effects on multiple metabolic pathways which results in cell growth inhibition. Cytotoxic antibiotics which come from microbial sources block mammalian cell division through multiple pathways which include DNA intercalation and topoisomerase inhibition.

The natural compounds which plants produce, including taxanes and camptothecins and vinca alkaloids, mainly disrupt microtubule activity which leads to disturbances in mitotic spindle development and prevention of cell division. Hormonal agents consist of steroid-based hormones which include glucocorticoids and estrogens and androgens together with medications that block hormone discharge or disrupt hormone receptor signaling, which play a crucial role in treating cancers that respond to hormonal treatment.

Table 1 Anticancer Agents with Different Mechanisms of Action.

| SL.NO | DRUG NAME                                                                                          | TYPE                                                                                                            | TYPE OF CANCER TREATED                            |
|-------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
| 1     | mechlorethamine, cyclophosphamide, ifosfamide, melphalan/sarcolysin, chlorambucil                  | Alkylating agent (nitrogen mustard)                                                                             | acute and chronic lymphocytic leukemia, etc.      |
| 2     | altretamine, thiotepa, procarbazine (N-methylhydrazine, MIH), busulfan                             | alkylating agent (ethyleneimines and methylmelamines, methylhydrazine derivative, alkyl sulfonate nitrosoureas) | ovarian, bladder, breast cancer, etc              |
| 3     | methotrexate (formerly amethopterin)                                                               | Anti-metabolites (folic acid analogues)                                                                         | breast, head, neck, and lung cancer               |
| 4     | fluorouracil (5-fluorouracil, 5-FU), capecitabine, cytarabine (also known as cytosine arabinoside) | antimetabolites (pyrimidine analogues)                                                                          | breast, colon, esophageal, stomach                |
| 5     | hydroxyurea, tretinoin, arsenic trioxide, imatinib                                                 | miscellaneous agents substituted urea differentiating agents, protein tyrosine kinase                           | chronic myelogenous, acute promyelocytic leukemia |
| 6     | paclitaxel, docetaxel, etoposide                                                                   | natural and semi-synthetic products, taxanes, epipodophyllotoxins                                               | ovarian, breast, lung, head, and neck cancer      |
| 7     | vinblastine, vinorelbine, vincristine                                                              | natural and semi-synthetic products, Vinca alkaloids                                                            | Hodgkin's disease; non-Hodgkin's lymphoma         |

➤ *Recently Discovered Anticancer Drugs:*

Anticancer medications have many limitations including resistance by chemicals in cancer cells, numerous adverse effects, and the fact that they affect both cancer and healthy cells. Heterocyclic compounds exhibit diverse pharmacological activities. Hormones, vitamins, antibiotics, and other biological compounds found in living organisms are composed of heterocyclic molecules. While heterocyclic compounds with a sulfur atom account for the bulk of FDA-approved drugs, heterocyclic compounds with a nitrogen

atom are regarded to be the most common type of chemical material utilized in medicinal chemistry. Many physiologically active natural products used in conventional treatment or approved prescription medications contain nitrogen-containing heterocyclic compounds. Many of their synthetic equivalents are available in the therapeutic market to treat a range of ailments. This article discusses the anticancer activity of numerous heterocyclic compounds and derivatives as well as their structures in vitro activity and IC50 values.

Table 2 Anticancer Drugs Recently Approved By The FDA

| SL.NO | DRUG NAME         | TYPE OF CANCER TREATED                                         |
|-------|-------------------|----------------------------------------------------------------|
| 1     | retifanlimab-dlwr | metastatic or recurrent locally advanced Merkel cell carcinoma |
| 2     | enfortumab        | locally advanced or metastatic urothelial carcinoma            |
| 3     | epcoritamab-bysp  | relapsed or refractory diffuse large B-cell lymphoma           |
| 4     | glofitamab-gxbm   | relapsed or refractory diffuse large B-cell lymphoma           |

|   |                 |                                         |
|---|-----------------|-----------------------------------------|
| 5 | talquetamab-tgv | relapsed or refractory multiple myeloma |
|---|-----------------|-----------------------------------------|

## II. MAJOR CLASSES OF HETEROCYCLIC COMPOUNDS WITH ANTICANCER ACTIVITY

### ➤ Indole Derivatives:

Researchers study indole derivatives because these nitrogen-containing heterocyclic compounds show potential as anticancer treatments. The indole core structure combines a benzene ring and a pyrrole ring which enables the molecule to form various structural shapes that bind with DNA and

enzymes and signaling proteins to control cell growth and programmed cell death and cancer spreading. Natural compounds such as indole-3-carbinol and synthetic derivatives like sunitinib and panobinostat exhibit potent cytotoxic activity against multiple cancer cell lines. The C-2 and C-3 sites together with heterocycle combinations will produce better results through modified approaches. The indole scaffold maintains its importance as a foundation for creating new anticancer drugs.




Fig 2 Synthetic and Natural Indole Derivatives

### ➤ Imidazole Derivatives:

Researchers study anticancer properties of Imidazole derivatives which are five-membered nitrogen-containing heterocyclic compounds. The imidazole ring contains three carbon atoms and two non-adjacent nitrogen atoms, which create hydrogen bonding capability and metal ion coordination capacity that lead to enhanced DNA and enzyme and signaling protein interaction. The derivatives

demonstrate cytotoxic effects by blocking cell growth and causing programmed cell death and changing cancer-related biological processes. Metronidazole-based derivatives and clotrimazole analogs and synthetic imidazole-linked compounds demonstrate effectiveness against breast cancer and lung cancer and colon cancer cell lines. The C-2 and C-4/C-5 position structural changes lead to enhanced potency and selectivity and improved pharmacokinetic properties.




Fig 3 Synthetic Imidazole Derivatives

#### ➤ Triazole Derivatives:

Researchers investigate triazole derivatives which form five-membered nitrogen-rich heterocycles that contain three nitrogen atoms in their ring structure since these compounds display anticancer properties. The isomeric forms of this compound exist as 1,2,3-triazole and 1,2,4-triazole which both demonstrate strong hydrogen bonding capacity and coordination ability that enable them to interact with DNA and enzymes and signaling proteins. The triazole derivatives

test their ability to fight cancer through three mechanisms which include stopping cancer cell growth and causing cancer cell death and changing vital biological processes that support tumor development and cancer spread. The different ring substitution positions create compounds that display increased bioactive effects with higher target selectivity and improved drug absorption characteristics. The compound letrozole targets breast cancer while synthetic triazole-linked cytotoxic compounds attack multiple cancer cell lines.




Fig 4 Synthetic Triazole Derivatives

### ➤ Benzimidazole Derivatives:

Benzimidazole derivatives are fused heterocyclic compounds which feature a benzene ring that joins together with an imidazole ring to create a fixed flat structure. The scaffold permits binding to DNA and enzymes and cellular proteins which results in the ability to control cell growth and programmed cell death and blood vessel formation. Benzimidazole derivatives display strong anticancer effects

against various cancer cell lines which include breast cancer and colon cancer and lung cancer and leukemia. C-2 C-5 and N-1 position structural changes enhance both selectivity and potency and drug performance. The list of compounds includes albendazole and omeprazole-based derivatives and current research examines synthetic benzimidazole analogs for use in targeted chemotherapy.




Fig 5 Synthetic Benzimidazole Derivatives

### ➤ Thiazole Derivatives:

Thiazole derivatives are five-membered heterocyclic compounds that contain one nitrogen atom and one sulfur atom at their 1 and 3 positions respectively. The heteroatomic structure of this compound system enables it to bind with DNA and enzymes and signaling proteins which leads to the prevention of cell growth and the activation of programmed cell death and the interruption of pathways linked to tumors.

Thiazole derivatives demonstrate strong anticancer effects against multiple cancer cell lines which include breast cancer and colon cancer and lung cancer. The C-2 C-4 and C-5 position structural alterations lead to improved drug effects and selectivity and drug absorption and distribution. The compounds tiazofurin and synthetic thiazole-based compounds serve as examples of targeted chemotherapy-designed pharmaceuticals.




Fig 6 Synthetic Thiazole Derivatives

### III. HETEROCYCLIC SCAFFOLD

Heterocyclic scaffolds, particularly those containing nitrogen, sulfur, and oxygen, are fundamental in cancer therapy, with over 85% of FDA-approved drugs containing these heterocycles. The main scaffolds used for testing their ability to block cancer cell growth and cause cancer cell death include indoles and quinolines as well as thiazoles and imidazoles. The structures of these compounds allow them to target kinases and topoisomerases while also binding to DNA, which enables the creation of specific and effective anticancer drugs.

#### ➤ Mechanism of Anticancer Activity:

Heterocyclic compounds can inhibit cancer progression through multiple mechanisms:

- **DNA Intercalation and Damage:**

The DNA intercalation ability of some heterocycles, which includes quinolines and acridines, results in DNA replication and transcription disruption that causes cellular apoptosis.

- **Enzyme Inhibition:**

Enzyme inhibition occurs when nitrogen-containing heterocycles block essential enzymes which support cell growth, including topoisomerases and kinases and histone deacetylases (HDACs).

- **Signal Pathway Modulation:**

Compounds that include imidazoles and pyrazoles function as signaling pathway modulators because they affect the PI3K/Akt and MAPK pathways, which cause cell cycle arrest and apoptosis.

- **Oxidative Stress Induction:**

Some sulfur- and nitrogen-containing heterocycles can produce reactive oxygen species (ROS) that specifically destroy cancer cells.




Fig 7 Various Heterocyclic Compounds




Fig 8 Mechanism of Action of Anti-Cancer Agents

#### IV. RECENT ADVANCES IN HETEROCYCLIC ANTICANCER DRUG DESIGN

Recent developments in medicinal chemistry have improved the discovery of heterocyclic anticancer agents through several approaches:

##### ➤ Structure–Activity Relationship (SAR) Insights:

Heterocyclic compounds remain a vital element in anticancer drug discovery because their different chemical structures and adjustable physicochemical characteristics and ability to bind with various biological targets. The recent SAR research developments permit chemists to study functional groups together with molecular features which improve their ability to target specific molecules while delivering therapeutic benefits. The research demonstrates that specific substituents from the electron-withdrawing and electron-donating groups on indole and imidazole and triazole and thiazole cores create derivatives which bind more effectively to essential enzymes such as kinases and topoisomerases and histone deacetylases. The process of SAR analysis enables scientists to develop better heterocyclic scaffolds which achieve higher cytotoxicity and selectivity against cancer cells.

##### ➤ Computational Drug Design:

Computational methods begin to establish their potential for creating new heterocyclic compounds because these methods enable scientists to predict which biological forms of compounds will show medicinal effects and which compounds should be selected for laboratory testing. The

combination of molecular docking and pharmacophore modeling and quantitative structure–activity relationship (QSAR) analyses with high-throughput screening (HTS) delivers quick results that identify effective leads for testing against different cancer cell lines. The drug discovery process has become more efficient because these methods enable researchers to explore biomolecular pathways that were previously difficult to study.

##### ➤ Hybrid Heterocyclic Compounds

The creation of hybrid heterocycles through their combination of two or more pharmacophores into a unified molecular structure represents an effective method for developing drugs that can treat multiple cancer targets. The combined effects of hybrids lead to two different results because they stop DNA replication process and they start the cell death process known as apoptosis. The indole–triazole and benzothiazole–quinoline derivatives show increased cancer-fighting power against drug-resistant tumor models.

##### ➤ Nanotechnology-Based Delivery

The combination of heterocyclic drugs with nanotechnology-based delivery systems creates new ways to treat medical conditions. The use of nanoparticles liposomes and polymeric carriers for drug encapsulation provides better solubility and stability and tumor-specific accumulation and reduced systemic toxicity. The advanced delivery systems provide targeted therapy with extended circulation time and improved pharmacokinetic and pharmacodynamic effects which benefit heterocyclic compounds that have low bioavailability.

### ➤ Green Chemistry Approaches

Eco-friendly synthesis methods are being developed for heterocyclic compounds to reduce environmental impact.

### ➤ Applications:

They function by inhibiting cell signaling, inducing apoptosis, disrupting angiogenesis, and damaging DNA.

- Targeted Therapy & Enzyme Inhibition: Heterocycles effectively bind to enzyme active sites. They act as inhibitors of tyrosine kinases (e.g., Dabrafenib for melanoma) and Heat Shock Protein 90 (Hsp90), which are critical for cancer cell survival.
- Chemotherapy Agents: Nitrogen-containing heterocycles like pyridines, indoles, and quinolines are extensively used in disrupting cell mitosis.
- Combination Therapy: Sulfur-based heterocycles (e.g., sulforaphane) can enhance the effectiveness of radiation or chemotherapy by sensitizing cancer cells.
- Drug Design: Due to their structural versatility, these compounds are frequently used to create derivatives with reduced toxicity and high potency against specific cancer cell lines.
- Agriculture: Heterocycles are widely applied as active ingredients in herbicides, insecticides, and fungicides due to their high selectivity and efficacy.
- Biochemicals and Life Sciences: They are essential to life, forming the structure of DNA/RNA bases (purines and pyrimidines), vitamins (e.g., Vitamin B<sub>1</sub> and B<sub>6</sub>), and chlorophyll.

### ➤ Challenges in Heterocyclic Anticancer Drug Development

Despite significant progress, several challenges remain:

- Development of drug resistance.
- Toxicity and side effects.
- Poor bioavailability of some compounds.
- Difficulty in selective targeting of cancer cells.

The solution to these challenges needs multiple scientific fields which include medicinal chemistry and molecular biology together with nanotechnology.

### ➤ Recent Trends

- Hybrid molecules: Combining heterocyclic scaffolds with other bioactive molecules to enhance potency.
- Metal complexes: Heterocyclic ligands coordinating with metals (e.g., platinum, ruthenium) for targeted cytotoxicity.
- Computational drug design: Using heterocyclic libraries to predict anticancer activity via docking and molecular simulations.

## V. CONCLUSION

Heterocyclic compounds have established themselves as essential elements in the process of discovering anticancer drugs because these compounds show both diverse chemical

structures and wide-ranging biological properties. The presence of heteroatoms which include nitrogen and oxygen and sulfur in cyclic structures allows these compounds to target specific biological components, which results in their ability to control pathways that lead to cancer development. The development of synthetic chemistry techniques together with molecular modeling advancements and computational drug design methods has enabled scientists to create heterocyclic scaffolds which possess improved drug absorption and body distribution characteristics, which results in better drug efficacy and more precise cancer treatment results.

The compounds achieve their anticancer properties through various biochemical pathways. Numerous compounds function as enzyme inhibitors, which block vital proteins that include kinases and topoisomerases and histone-modifying enzymes, which scientists consider crucial for tumor development and survival. The others bind with DNA through intercalation between base pairs or permanent chemical bonds with DNA, which causes cells to experience replication difficulties and DNA destruction, resulting in their eventual death. Several heterocyclic derivatives initiate apoptosis through their ability to trigger either intrinsic or extrinsic signaling pathways, while others create cell cycle arrest which stops cancer cells from multiplying.

The ability of these molecules to target multiple pathways simultaneously makes them particularly valuable in overcoming drug resistance, a major challenge in conventional chemotherapy. The ongoing investigation in this field will create new anticancer drugs that show improved ability to target cancer cells while demonstrating enhanced safety and effectiveness. The combination of heterocyclic scaffolds with contemporary methodologies, such as hybrid drug design and metal coordination complexes and high-throughput screening, will lead to the discovery of new molecular entities.

## REFERENCES

- [1]. Mir, M. A., et al. *Heterocyclic Phytochemicals as Anticancer Agents* – detailed review of natural heterocyclic compounds and anticancer mechanisms.
- [2]. Santali, E. Y. *Recent Developments of Quinoline-Heterocyclic Conjugates as Anticancer Agents* – focuses on quinoline-based hybrids.
- [3]. Sudhakar, M., et al. *A Review on Heterocyclic Anticancer Compounds: Recent Advances (2024)* – overview of mechanisms and design.
- [4]. Sahil, Kaur & Jaitak. *Thiazole and Related Heterocyclic Systems as Anticancer Agents* – SAR, synthesis & mechanisms.
- [5]. Kumar, A., et al. *Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective* – comprehensive medicinal chemistry review.
- [6]. Alrooqi, M., et al. *A Therapeutic Journey of Pyridine-based Heterocyclic Compounds as Potent Anticancer Agents* – focuses on pyridine derivatives (2017–2021).

- [7]. Al-Jumaili, M. H. A., et al. *Development of Heterocyclic-based Anticancer Agents: A Comprehensive Review* – broad review of heterocyclic drugs and mechanisms.
- [8]. Bistrović, A.; Krstulović, L.; Harej, A.; Grbčić, P.; Sedić, M.; Koštrun, S.; Pavelić, S. K.; Bajić, M.; Raić-Malić, S. *Eur. J. Med. Chem.* 2018, 143, 1616.
- [9]. Akunuri, R.; Vadakattu, M.; Bujji, S.; Veerareddy, V.; Madhavi, Y. V.; Nanduri, S. *Eur. J. Med. Chem.* 2021, 220, 113445.
- [10]. Amin, M. M.; Abuo-Rahma, G. E.-D. A.; Shaykoon, M. S. A.; Marzouk, A. A.; Abourehab, M. A. S.; Saraya, R. E.; Badr, M.; Sayed, A. M.; Beshr, E. A. M. *Bioorg. Chem.* 2023, 134, 106444
- [11]. Ilovaisky, A. I.; Scherbakov, A. M.; Merkulova, V. M.; Chernoburova, E. I.; Shchetinina, M. A.; Andreeva, O. E.; Salnikova, D. I.; Zavarzin, I. V.; Terent'ev, A. O. *J. Steroid Biochem. Mol. Biol.* 2023, 228, 106245.
- [12]. Bray, F.; Laversanne, M.; Weiderpass, E.; Soerjomataram, I. *Cancer* 2021, 127, 3029.
- [13]. Ramurthy, S.; Subramanian, S.; Aikawa, M.; Amiri, P.; Costales, A.; Dove, J.; Fong, S.; Jansen, J. M.; Levine, B.; Ma, S.; McBride, C. M.; Michaelian, J.; Pick, T.; Poon, D. J.; Girish, S.; Shafer, C. M.; Stuart, D.; Sung, L.; Renhowe, P. A. *J. Med. Chem.* 2008, 51, 7049.
- [14]. Kaur, A., Shakya, A. K., Singh, R., Badhwar, R., & Sawhney, S. K. Heterocyclic Compounds and their Derivatives with Potential Anticancer Activity. *Indian Journal of Pharmaceutical Education and Research*, 58(1 Suppl), S26-S39 (2024). Review of diverse heterocyclic rings (N, S, O) and anticancer activity.
- [15]. Sachdeva, H., Mathur, J., & Guleria, A. Indole Derivatives as Potential Anticancer Agents: A Review. *Journal of the Chilean Chemical Society* (2020). Focuses on indole-based heterocycles and their anticancer potential with mechanisms.
- [16]. Goel, N., & Kumar, N. Heterocyclic Compounds: Importance in Anticancer Drug Discovery. *Anti-Cancer Agents in Medicinal Chemistry* (2022). Indian researchers discuss heterocyclic scaffolds and anticancer drug design.
- [17]. Varshney, S., Tiwari, A., & Mishra, R. N-Heterocyclic Analogs: A New Prospect in Cancer Therapy. *Asian Journal of Chemistry*, 35(10), 2323-2335 (2023). Summary of nitrogen-containing heterocycles and anticancer activities.
- [18]. Williams, D. A., Lemke, T. L., & Roche, V. F. *Foye's Principles of Medicinal Chemistry*. Wolters Kluwer, 7th ed., 2013.
- [19]. Sharma, V., Chitranshi, N., & Agarwal, A. K. (2014). *Significance and biological importance of heterocyclic compounds in drug discovery*. *Bioorganic & Medicinal Chemistry*, 22(1), 1–16.
- [20]. Kumar A. et al., Nitrogen Containing Heterocycles as Anticancer Agents, 2023.
- [21]. Michael JP. Heterocyclic compounds in medicinal chemistry, *Natural Product Reports*.
- [22]. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, John Wiley & Sons.